Cell Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cell Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030

Cell Therapy Market By Type (Autologous And Allogenic), By Cell Type (Stem Cell And Non-Stem Cell), By Indication (Oncological, Cardiovascular, And Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising therapeutic value of cell therapy and surge in research and development activities for cell therapy

The global cell therapy market is estimated to grow at a CAGR of 14.34% during the forecast period from 2024 to 2030. The demand for cell therapy is primarily being boosted by the rising incidence of oncological disorders such as blood cancer, and others, the surge in cases of critical limb ischemia (CLI), increasing R&D and investments for cell therapy, and growing advances in technologies employed for manipulation and administration of cell therapies among other factors are further contributing in the overall growth of the cell therapy market during the forecast period from 2024-2030.

Cell Therapy Market Dynamics:

According to Global Cancer Observatory 2020 data, globally around 544,352 cases of Non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020. As per the same source globally around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020. The above-mentioned source further stated that in 2020 Asia recorded 273,012 new cases of Hodgkin and non-Hodgkin lymphoma and had the highest prevalence for Hodgkin and non-Hodgkin lymphoma, followed by Europe (142,837), North America (91,262), and Africa (61,331).

Cell therapy is becoming a prominent treatment option for blood cancers. For example, Kymriah by Novartis AG is the first chimeric antigen receptor (CAR) T cell immunotherapy approved by the US Food and Drug Administration for the treatment of adult patients with relapsed or refractory follicular lymphoma.

The surge in strategic activities on cell therapy is also expected to drive the market for cell therapy. For instance, in October 2022 Century Therapeutics and Bristol Myers Squibb entered into a strategic collaboration to develop iPSC-derived allogeneic cell therapies.

Similarly, in November 2022 AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc., a global clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.

However, challenges associated with cell therapy manufacturing and the very high treatment cost of cell therapy may restrict the growth of the overall cell therapy market.

The cell therapy market was largely impacted during the period of COVID- 19 pandemic owing to lockdown impositions as a measure to prevent the spread of COVID-19 infection which led to the suspension of research and development activities based on cell therapy owing to the lack of availability of raw materials and required workforce. Nevertheless, the cell therapy market is in a recovery phase owing to the introduction of vaccines against COVID-19 and the resumption of activities across all sectors including healthcare and pharmaceutical, thereby providing ample opportunities for the cell therapy market to grow at significant revenue during the forecast period.

Cell Therapy Market Segment Analysis:

Cell Therapy Market by Type (Autologous and Allogenic), By Cell Type (Stem Cell and Non-Stem Cell), By Indication (Oncological, Cardiovascular, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the cell therapy market, the autologous category is expected to amass a significant revenue share in the year 2023.

In autologous cell therapy, the patient’s self-cells are used to replace the damaged cells. The patient provides their cells as a starting point for autologous therapy. Then, as a therapeutic intervention, these cells are cultivated, multiplied, and altered ex vivo, or outside of the body, and returned to the patient. Autologous therapy is specifically tailored for the patient and cannot be given to anybody else.

The use of auto or self-cells for disease treatment minimizes the risks of systemic immunological reactions and increases the chance of getting accepted by the body’s immune system. There is less chance of harmful autoimmune post-transplant problems such as graft versus host disease (GvHD) through autologous cell therapy. The risk for disease transmission associated with grafts or cells not cultivated from the individual is eliminated.

It has been established that autologous therapies can considerably enhance patient clinical outcomes or treat common and uncommon disorders. For example, Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with multiple myeloma.

Also, numerous autologous cell therapy-based drugs are being developed for various rare indications which are likely to boost their demand in coming years. For example, Immusoft’s ISP-001, an investigational engineered autologous B-cell therapy intended for the treatment of mucopolysaccharidosis type I (MPS I) received the US FDA approval for initiating a phase I clinical trial.

Therefore, considering the advantages associated with autologous cell therapy and its growing usage, this category is expected to generate considerable revenue thereby pushing the overall growth of the global cell therapy market during the forecast period.

North America is expected to dominate the overall Cell Therapy Market:

Among all the regions, North America is estimated to account for the largest share of the cell therapy market in the year 2023. Owing to the significance of key growth factors such as the increasing patient population suffering from cancer, sophisticated healthcare infrastructure, the presence of key players, and fast regulatory approval for new products, among others, the market for cell therapy is expected to register significant growth in the region.

As per Globocan 2020 data, there were around 61,152 new cases of leukemia recorded in 2020. As per the same source around 73,652 cases of Non-Hodgkin lymphoma and 8,107 new cases of Hodgkin lymphoma were recorded in 2020 in the US.

As per the above-mentioned source by 2040 there will be around 100 thousand new cases of non-Hodgkin lymphoma and about 9.22 thousand new cases of Hodgkin lymphoma reported in the United States. The data published by the American Cancer Society 2023 states that about 35,730 new cases of multiple myeloma are going to be reported in 2023 in the United States.

The rising number of product development activities in the region is further going to accelerate the growth of the cell therapy market. For example, in June 2022, Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).

Hence, the above-mentioned factors are going to increase the growth of the cell therapy market in the region.

Cell Therapy Market Key Players:

Some of the key market players operating in the cell therapy market include Cipla, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, Gilead Sciences, Inc., Atara Biotherapeutics, Inc., Takeda Pharmaceutical Company Limited, Tegoscience, Kolon TissueGene, Inc., IMMUSOFT, and others.

Recent Developmental Activities in the Cell Therapy Market:

In February 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the company has received US FDA approval for CARVYKTI™ intended for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

In April 2022, Kite, a Gilead Company received US FDA approval for Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

Key Takeaways from the Cell Therapy Market Report Study

Market size analysis for current cell therapy market size (2023), and market forecast for 6 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the cell therapy market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global cell therapy market.

Various opportunities available for the other competitor in the cell therapy market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current cell therapy market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for cell therapy market growth in the coming future?

Target Audience who can be benefited from this Cell Therapy Market Report Study

Cell Therapy products providers

Research organizations and consulting companies

Cell therapy-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in cell therapy

Various End-users who want to know more about the cell therapy market and the latest innovations and developments in the cell therapy market.

Frequently Asked Questions for the Cell Therapy Market:

1. What is cell therapy?

Cell therapy includes replacing diseased or damaged cells with new, healthy ones, altering the function of the patient's cells by the production of factors or direct interaction, and utilizing immune cells to remove disease-causing or malfunctioning cells.

2. What is the market for global cell therapy?

The global cell therapy market is estimated to grow at a CAGR of 14.34% during the forecast period from 2024 to 2030.

3. What are the drivers for the global cell therapy market?

The growth of the cell therapy market is primarily being boosted by the increasing therapeutic importance of cell therapy, growing adoption for regenerative medicine, rising research and development activities related to cell therapy, and growing knowledge of the biology of disease and significant advancements in gene editing, protein engineering, and cell culture technology among others, are contributing to the overall growth of the cell therapy market during the forecast period from 2024-2030.

4. Who are the key players operating in the global cell therapy market?

Some of the key market players operating in the cell therapy market include Cipla, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, Gilead Sciences, Inc., Atara Biotherapeutics, Inc., Takeda Pharmaceutical Company Limited, Tegoscience, Kolon TissueGene, Inc., IMMUSOFT, and others.

5. Which region has the highest share in the cell therapy market?

North America is expected to dominate the overall cell therapy market during the forecast period from 2024-2030. Factors such as the increasing patient population suffering from genetic disorders, the rising incidence of cancer, sophisticated healthcare infrastructure, the presence of key players, and fast regulatory approval for new products, among others, are driving the growth of the cell therapy market in the region.